2. Tempus AI Inc. (NASDAQ:TEM)
Tempus AI, Inc. (NASDAQ: TEM) claims the No. 2 position as the strongest pure-play AI precision medicine company in the ranking. The business combines molecular testing, clinical data and artificial intelligence to help doctors make more informed treatment decisions, particularly in cancer care.
The company has built an extensive library of clinical and molecular information. AI models can analyze this data to identify patterns, predict treatment responses and support the development of new medicines. The same infrastructure can serve hospitals, physicians, biotechnology companies and pharmaceutical researchers.
This creates two major revenue streams. The diagnostics operation processes genomic and molecular tests, while the Data and Applications segment generates revenue through data licensing, modeling and healthcare software. The combination makes the company more commercially developed than many AI drug-discovery firms that depend almost entirely on future clinical milestones.
Second-quarter 2026 revenue rose 22% to $382.5 million. Diagnostics revenue reached $289.3 million, supported by 31% growth in oncology testing volume. Data and Applications revenue increased 28% to $93.2 million, while data licensing and modeling revenue advanced 36%. Gross profit climbed 26% to $246.5 million. The company disclosed the growth figures in its second-quarter earnings release.
Those results confirm that AI-driven precision medicine is already producing meaningful commercial revenue. The company is not simply presenting an experimental technology and promising that customers will eventually arrive.
The main concern is valuation. At approximately $64.62 per share, its market capitalization approaches $12 billion despite continuing GAAP losses. That makes it one of the best medical AI companies in the public market, but not necessarily one of the cheapest based on present earnings.
The stock could still deliver major long-term gains if the company becomes a central data platform for precision healthcare. Its large dataset, growing diagnostics business and relationships across the medical industry could form a durable competitive advantage. Investors must nevertheless accept that much of this future success is already reflected in the valuation.
